Advanced search
Publication Cover
Scandinavian Journal of Infectious Diseases Volume 22, 1990 - Issue sup72
Submit an article Journal homepage
27
Views
0
CrossRef citations to date
0
Altmetric
Miscellany

Perspectives on Teicoplanin: Proceedings of a Symposium within the 7th Mediterranean Congress of Chemotherapy, Barcelona, 22 May 1990

Richard Wise
Pages 1-67 | Published online: 02 Jan 2015

References

  • Verbist L, Tjandramaga B, Hendrickx B, van Hecken AN, van Melle P, Verbesselt R, Veregen J, de Schepper PJ. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother 26: 881–886, 1984
  • Buniva G, del Favero A, Bernareggi A, Patoia L, Palumbo R. Pharmacokinetics of 14C-teicoplanin in healthy volunteers. J Antimicrob Chemother 21 ( Suppl A): 23–28, 1988
  • Verbist L. Teicoplanin pharmacokinetics: Multiple dose study. In: Gialdroni-Grassi G, Mitsuahashi S, Williams JD, eds. Proceedings of a Workshop Held at the 14th International Congress of Chemotherapy, Kyoto 1986. University of Tokyo Press, 15–19, 1985.
  • Assandri A, Bernareggi A. Binding of teicoplanin to human serum albumin. Eur J Clin Pharmacol 33: 191–195, 1987
  • Boeckh M, Lode H, Borner K, Höffken G, Wagner J, Koeppe P. Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob Agents Chemother 32: 92–95, 1988
  • Lode H, Boeckh M, Höffken G, Borner U, Koeppe P. Pharmakokinetik von Teicoplanin und Vergleich zu Vancomycin. Fortschritte der anti-mikrobiellen und anti-tumorösen Chemotherapie: 8 (1990). In press.
  • Wise R, Donovan IA, McNulty CAM, Waldron R, Andrews JM. Teicoplanin, its pharmacokinetics, blister and peritoneal fluid penetration. J Hosp Infect 7 ( Suppl A): 47–55, 1986

References

  • Archer GL, Johnston JL, Vazquez GJ, Haywood HB III. Efficacy of antibiotic combinations including rifampicin against methicillin-resistant Staphylococcus epidermidis: In vitro and in vivo studies. Rev Infect Dis 5 ( Suppl 3): 538–542, 1983
  • Simon C, Stille W. Antibiotika-Therapie in Klinik und Praxis. Schattauer Verlag 7. Auflage S. 205, 1989
  • Jensen K. Methicillin-resistant staphylococci. Lancet 2: 1078, 1968
  • Jensen K, Lassen HCA. Combined treatment with antibacterial chemotherapeutical agents in staphylococcal infections. Q J Med, New Series XXXVIII, 149: 91–106, 1969
  • Faville JR Jr, Zaske DE, Kaplan EL, Crossley K, Sabath LD, Quie PG. Staphylococcus aureus endocarditis. Combined therapy with vancomycin and rifampin. JAMA 240: 1963–1965, 1978
  • Archer GL, Tenenbaum MJ, Haywood HB III. Rifampin therapy of Staphylococcus epidermidis. Use in infections from indwelling artificial devices. JAMA 240: 751–753, 1978
  • Sande MA, Scheld WM. Combination antibiotic therapy of bacterial endocarditis. Ann Intern Med 92: 390–395, 1980
  • Debbia E, Pesce A, Schito GC. In vitro interactions between teicoplanin and other antibiotics against enterococci and staphylococci. J Hosp Infect 7 ( Suppl A): 73–77, 1986
  • Dixson S, Brumfitt W, Hamilton-Miller JMT. In vitro activity of combinations of antibiotics against staphylococcus aureus resistant to gentamicin and methicillin. Infection 13: 43–46, 1985
  • Georgopoulos A. Aktivität von Teicoplanin und In-vitro-Synergismus bei Kombination mit anderen Chemotherapeutika. Fortschritte der Antimikrobiellen Chemotherapie (FAC) 8: 8–12, 1989
  • Hackbarth CJ, Chambers HF, Sande MA. Serum bactericidal activity of rifampicin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother 29: 611–613, 1986
  • Kissling M, Bergamini N. Rifampicin in free combination with other antimicrobial drugs in non-Tb infections. Chemotherapy 27: 368–402, 1981
  • Varaldo PE, Debbia E, Schito GC. In vitro effects of vancomycin and rifampicin, alone and in combination, against methicillin-sensitive and methicillin-resistant staphylococci. J Antimicrob Chemother 14 ( Suppl D): 35–41, 1984
  • Varaldo PE, Debbia E, Schito GC. In vitro activity of teichomycin and vancomycin alone and in combination with rifampicin. Antimicrob Agents Chemother 23: 402–406, 1983
  • Walsh TJ, Auger F, Tatem BA, Hansen SL, Standiford HC. Novobiocin and rifampicin in combination against methicillin-resistant Staphylococcus aureus: An in vitro comparison with vancomycin plus rifampicin. J Antimicrob Chemother 17: 75–82, 1986
  • Watanakunakorn C, Guerriero JC. Interaction between vancomycin and rifampicin against Staphylococcus aureus. Antimicrob Agents Chemother 19: 1089–1091, 1981
  • Tuazon CU, Lin MYC, Sheagren JN. In vitro activity of rifampicin alone and in combination with nafcillin and vancomycin against pathogenic strains of Staphylococcus aureus. Antimicrob Agents Chemother 13: 759–761, 1978
  • Bayer AS, Lam K. Efficacy of vancomycin plus rifampicin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: In vitro–in vivo correlations. J Infect Dis 151: 157–165, 1985
  • Newsom SWB. The treatment of endocarditis by vancomycin. J Antimicrob Chemother 14 ( Suppl D): 79–84, 1984

References

  • Tilghman RC, Finland M. Clinical significance of bacteraemia in pneumococcal pneumonia. Arch Intern Med 59: 602–619, 1937
  • Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 60: 759–776, 1964
  • Gransden WR, Eykyn SJ, Phillips I. Pneumococcal bacteraemia: 325 episodes diagnosed at St. Thomas's Hospital. Br Med J 290: 505–508, 1985
  • Kramer MR, Rudensky B, Hadas-Halperin I, Isacsohn M, Melzer E. Pneumococcal bacteraemia—no change in mortality in 30 years: Analysis of 104 cases and review of the literature. Isr J Med Sci 23: 174–180, 1987
  • Klugman KP. Pneumococcal resistance to antibiotics. Clin Micro Rev 3: 171–196, 1990
  • Robins-Browne RM, Gaspar MN, Ward JI, Wachsmuth IK, Koornhof HJ, Jacobs MR, Thornsberry C. Resistance mechanisms of multiply-resistant pneumococci: Antibiotic degradation studies. Antimicrob Agents Chemother 15: 470–474, 1979
  • Tomasz A. Biochemistry and genetics of penicillin resistance in pneumococci. In: Ferretti JJ, Curtis R III, eds. Streptococcal genetics. Washington DC: American Society for Microbiology, 87–92, 1987
  • Koornhof HJ, Jacobs MR, Ward JI, Appelbaum PC, Hallet FA. Therapy and control of antibiotic-resistant pneumococcal disease. In: Schlessinger D, ed. Microbiology—1979. Washington DC: American Society for Microbiology, 286–289, 1979
  • Parenti F, Beretta G, Berti M, Arioli V. Teichomycins, new antibiotics from Actinoplanes teichomyce-ticus nov. sp. J Antibiot 31: 276–283, 1978
  • Verbist L, Tjandramaga B, Hendrickx B, Van Hecken A, Van Melle P, Verbesselt R, Verhaegen J, de Schepper PJ. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother 26: 881–886, 1984
  • Condemi JJ. Allergy to penicillin and other antibiotics. In: Reese RE, Douglas RG Jr, eds. A practical approach to infectious diseases. Boston/Toronto: Little, Brown and Company, 680–697, 1986

References

  • Kaplan RA, Markman M, Lucas WE, Pfeifle C, Howell SB. Infectious peritonitis in patients receiving intraperitoneal chemotherapy. Am J Med 78: 49–53. 1985
  • Verbist L, Tjandramaga B, Hendrickx B, Van Hecken A, Van Melle P, Verbesselt R, Verhaegen J. Schepper PJ. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother 26: 881–886, 1984
  • Smith SR, Cheesbrough J, Spearing R, Davies JM. Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob Agents Chemother 33: 1193–1197, 1989
  • Van der Auwera P, Klastersky J. Bactericidal activity and killing rate of serum in volunteers receiving vancomycin or teicoplanin with or without amikacin given intravenously. J Antimicrob Chemother 19: 623–635, 1987
  • Peterson PK, Matzke G, Keane WF. Current concepts in the management of peritonitis in patients undergoing ambulatory peritoneal dialysis. Rev Infect Dis 9: 604–612, 1987

References

  • Sawchuk RJ, Rector TS. Drug kinetics in burn patients. Clin Pharmacokinet 5: 548–556, 1980
  • Zaske DE, Sawchuk RJ, Gerding DN, Strate RG. Increased dosage requirements of gentamicin in burn patients. J Trauma 16: 824–828, 1976
  • Loirat P, Rohan J, Baillet A, Beaufils F, David R, Chapman A. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. N Engl J Med 299: 915–919, 1978
  • Anonymous. Teicoplanin FPIA. Innotron Brochure, Portland, Oregon. Am Bioclin, May: 1–20, 1989
  • Ryaback MJ, Reddy VN, Matzke GR, Awhi WM, Peter WS, Mastin SH, Mayer GD, Kenny MT and FPIA Study Group. Teicoplanin Fluorescence Polarization Immunoassay. Pharmacotherapy 9: 188, 1989
  • Domart Y, Pierre C, Clair B, Garaud JJ, Regnier B, Gibert C. Pharmacokinetics of teicoplanin in critically ill patients with various degrees of renal impairment. Antimicrob Agents Chemother 31: 1600–1604, 1987
  • Rio Y, Giorgi C, Schockmel G, Didion J, Jurin F, Meley M, Tarral A. Traitement des septicémies et infections cutanées chez le brûlé par la teicoplanine. Etude de sa diffusion cutanée. Pathol Biol 35: 603–607, 1987
  • Greenwood D. Microbiological properties of teicoplanin. J Antimicrob Chemother 21 ( Suppl A): 1–13, 1988
  • Moellering RC Jr. Pharmacokinetics of vancomycin. J Antimicrob Chemother 14 ( Suppl D): 43–52, 1984
  • Zaske DE, Sawchuk RJ, Strate RG. The necessity of increased doses of amikacin in burn patients. Surgery 84: 603–608, 1978
  • Potel G, Meignier M, Baron D, Reynaud A, Touze MD, Courtieu AL. Pharmacokinetics of fosfomycin in normal and burn patients. Effect of probenecid. Drugs Exp Clin Res 15: 177–184, 1989
  • Drugeon HB, Pannier M, Courtieu AL. Pharmacocinétique de l'azlocilline chez le brûlé. Presse Med 13: 805–807, 1984
  • Ryback MJ, Albrecht LM, Berman JR, Warbasse LH, Svensson CK. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 34: 792–795, 1990
  • Garaud JJ, Regnier B, Inglebert F, Faurisson F, Bauchet J, Vachon F. Vancomycin pharmacokinetics in critically ill patients. J Antimicrob Chemother 14 ( Suppl D): 53–57, 1984
  • Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients. J Pharmacokinet Biopharm 4: 183–195, 1976
  • Glew RH, Moellering RC, Burke JF. Gentamicin dosage in children with extensive burns. J Trauma 16: 819–823, 1976
  • Buniva G, Del Favero A, Bernareggi A, Patoia L, Palumbo R. Pharmacokinetics of 14C-teicoplanin in healthy volunteers. J Antimicrob Chemother 21 ( Suppl A): 23–28, 1988
  • Potel G, Meignier M, Touzé MD, Drugeon HB, Baron D. Pharmacocinétique de la péfloxacine chez le brûlé. Pathol Biol 35: 777–780, 1987
  • Bernareggi A, Cavenaghi L, Assandri A. Pharmacokinetics of (14C) teicoplanin in male rats after single intravenous dose. Antimicrob Agents Chemother 30: 733–738, 1986

References

  • Terragna A, Ferrea G, Loy A, Danese A, Bernareggi A, Cavenaghi L, Rosina R. Pharmacokinetics of teicoplanin in pediatric patients. Antimicrob Agents Chemother 21: 1223, 1988
  • Tarral E, Jehl F, Tarral A, Simeoni U, Monteil H, Willard D, Geisert J. Pharmacokinetics of teicoplanin in children. J Antimicrob Chemother 21 ( Suppl A): 47–51, 1988
  • Lemerle S, de La Rocque F, Lamy R, Fremanx A, Bernaudin F, Labut JD, Reinert P. Teicoplanin in combination therapy for febrile episodes in neutropenic and non-neutropenic paediatric patients. J Antimicrob Chemother 21 ( Suppl A): 113–116, 1988
  • Kafetzis DA, Tsapra H, Gianacopoulou C, Karasmitos S. Clinical and pharmacokinetic study of teicoplanin in children. Abstract 1184, 15th International Congress of Chemotherapy, Istanbul, July 1987
  • Titone L, Romano A, Cascio A, Scarlata F. Teicoplanin in the treatment of children's infections by Gram-positive organism. Proceedings of the 16th International Congress of Chemotherapy, Jerusalem, June 1989, p. 14.
  • Tuo P, Silvestri G, Vallarino R, Pallecchi A, Balzarini C, Bracco C, Mantero E, Fossa S. Teicoplanin in a newborn intensive care unit. 16 Congresso della società Italiana di chemioterapia. Firenze, marzo 1989
  • Schaison GS, Arlet G, Leverger G, Douard MC, Garaud JJ. Infections due to coagulase-negative staphylococci in neutropenic children: Historical aspect and new trends in therapy. In: Ian Phillips, ed. Focus on coagulase-negative staphylococcal. Royal Society of Medicine Services International Congress and Symposium series no. 151: 35–44, 1989
  • Data on file. Merrell Dow Pharmaceuticals
  • Cruciani M, Navarra A, Di Perri G, Andreoni M, Danzi MC, Concia E, Bassetti D. Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections. Rev Infect Dis. In press.
  • Stillman TI, Wenzel RP, Donowitz LC. Emergence of coagulase negative staphylococcal as major nosocomial bloodstream pathogens. Infect Control 8: 108–112, 1987
  • Wenzel RP. The reemergence of Gram-positive cocci as major nosocomial pathogens. Infect Control 7: 118, 1986
  • Maple PAC, Hamilton-Miller JMT, Brumfitt W. World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus. Lancet i: 537–540, 1989

References

  • Finkelstein R, Sobel JD, Nagler A, Merzbach D. Staphylococcus aureus bacteremia and endocarditis: Comparison of nosocomial and community-acquired infection. J Med 15: 193–211, 1984
  • Peacock JE Jr, Marsik FJ, Wenzel RP. Methicillin-resistant Staphylococcus aureus: Introduction and spread within a hospital. Ann Intern Med 93: 526–532, 1980
  • Reynolds P. Glycopeptide activity, spectrum of activity, resistance patterns. Hosp Formul 25: 537–544, 1990
  • Williams AH. Comparative safety of teicoplanin and other Gram-positive agents. In: Grüneberg RN, ed. Teicoplanin further European experience. RSM Services International Congress and Symposium Series 156: 75–81, 1990
  • Williams AH, Grüneberg RN. Teicoplanin revisited. J Antimicrob Chemother 22: 397–402, 1988
  • Kloos WE, Jorgensen JH. Staphylococci. In: Manual of clinical microbiology, 4th ed. Lennette EH, Balows A, Hausler WJ Jr, Shadomy HJ, eds. Washington DC: American Society for Microbiology, 143–153, 1985
  • Jones RN, Barry AL, Gavan TL, Washington JA II. Susceptibility tests: Microdilution and macrodilution broth procedures. In: Manual of clinical microbiology, 4th ed. Lennette EH, Balows A, Hausler WJ Jr, Shadomy HJ, eds. Washington DC: American Society for Microbiology, 972–977, 1985

References

  • Keighley, MRB. Perioperative antibiotics. Br Med J 286: 1844–1846, 1983
  • Higgins AF, Lewis A, Noone P, Hole ML. Single and multiple dose cotrimoxazole and metronidazole in colorectal surgery. Br J Surg 67: 90–92, 1980
  • Brennan SS, Pickford IR, Evans M, Pollock AV. The prophylaxis of wound infection after abdominal operations: Is one dose of antibiotic enough? J Hosp Infect 3: 351–356, 1982
  • Antrum RM, Bibby SR, Ramsden CH, Kester RC. Teicoplanin: Part 1. An evaluation of the concentrations seen in serum and the subcutaneous fat of the relatively ischaemic lower limb following a single intravenous bolus. Drugs Exp Clin Res 15: 21–23, 1989
  • Williams AH, Gruneberg RN, Webster A. Ridgway GL. Teicoplanin in the treatment of infection caused by Gram-positive organisms. J Hosp Infect 7 ( Suppl A): 101–103, 1986
  • Nakayama I. BRL 25000-Augmentin: Clinical experience in the treatment of surgical and dermatological infections. In: Augmentin. Proceedings of the second symposium 17 July, 1981. Leigh DA, Robinson OPW, eds. Int Cong Ser 590: 165–178, 1982
  • Harding I, Garaud J-J. Teicoplanin in the treatment of infections caused by coagulase-negative staphylococci. J Antimicrob Chemother 21 ( Suppl A): 93–103. 1988
  • Arioli V, Berti M, Candiani G. Activity of teicoplanin in localized experimental infections in rats. J Hosp Infect 7 ( Suppl A): 91–99, 1986
  • Antrum RM, Bibby SR, Ramsden CH, Kester RC. Teicoplanin: Part 2. Evaluation of its use in the biliary system. Drugs Exp Clin Res 15: 25–27, 1989
  • Stille W, Sietzen W, Dieterich H-A, Fell JJ. Clinical efficacy and safety of teicoplanin. J Antimicrob Chemother 21 ( Suppl A): 69–79, 1988
  • Guidelines for detection of hepatotoxicity due to drugs and chemicals. Ed. Charles S Davidson, Carroll M Leevy, Earl C Chamberlayne. US Department of Health Education and Welfare, NIH Publication no. 79/313, 1979

References

  • Bauernfeind A, Petermüller C. In vitro activity of teichomycin A 2 in comparison with penicillin and vancomycin against gram-positive cocci. Eur J Clin Microbiol 1: 278–281, 1982
  • Verbist L, Tjandramaga B. Hendrick B, Van Hecken A, Van Melle P, Verbesselt R, Verhaegen J, De Schepper PJ. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother 26: 881–886. 1984
  • Traina GL, Bonati M. Pharmacokineties of teicoplanin in man after intravenous administration. J Pharmacokinet Biopharm 12: 119–128, 1984
  • McNulty CA, Garden GMF, Wise R, Andrews JM. The pharmacokinetics and tissue penetration of teicoplanin. J Antimicrob Chemother 16: 743–749. 1985
  • Neu HC, Labthavikul P. In vitro activity of teichomycin compared with those of other antibiotics. Antimierob Agents Chemother 24: 425–428, 1983
  • Pallanza R. Berti M. Goldstein BP. Teichomyein: In vitro and in vivo evaluation in comparison with other antibiotics. J Antimicrob Chemother 11: 419–425. 1983
  • Guenthner SH, Wenzel RP. In vitro activities of teichomycin, fusidic acid, flucloxacillin, fosfomycin, and vancomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 26: 268–269, 1984
  • Chandrasekar PH, Price S, Levine DP. In vitro evaluation of cefpirome (HR810), teicoplanin and four antimicrobials against enterococci. J Antimicrob Chemother 16: 179–182, 1985
  • Stille W, Sietzen W, Dietrich H-A, Fell JJ. Clinical efficacy and safety of teicoplanin. J Antimicrob Chemother 21 ( Suppl A): 69–79, 1988

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.